# APAC Infectious Disease Diagnosis Treatment Market

> Asia Pacific Infectious Disease Diagnosis & Treatment Market Research Report, By Applications (AIDS, Tuberculosis (TB), Hepatitis, HPV, And Others), By Treatment (Antibiotics, Antivirals, Antifungals, Anti-Parasitic, Alternative Medicine And Others), By Diagnostic Techniques (Immunoassays, PCR, Cell Cultures And Other), By End Users (Hospitals, Clinics, Reference Labs And Others) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 2.27%
- **2024:** $ 28.5 Billion
- **2025:** $ 29.15 Billion
- **2035:** $ 36.5 Billion
- **Key Players:** Abbott Laboratories (US), Roche Holding AG (CH), Thermo Fisher Scientific (US), Siemens Healthineers AG (DE), Becton Dickinson and Company (US), bioMérieux SA (FR), Cepheid (US), Hologic Inc. (US), QuidelOrtho Corporation (US)

**Report ID:** MRFR/MED/0814-HCR · **Pages:** 80 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/apac-infectious-disease-diagnosis-treatment-market-1322

---

## Market Summary

## **Asia Pacific Infectious Disease Diagnosis & Treatment Market Overview**

The APAC Infectious Disease Diagnosis & Treatment market is anticipated to reach USD 3.1 Billion by 2032 at a CAGR 2.9% during the forecast period 2023-2032.

The APAC infectious disease diagnosis & treatment market is anticipated to grow substantially in the years to come. The APAC  infectious illness diagnosis and treatment market value was estimated at around USD 179.58 Billion in the year 2018. APAC infectious disease diagnosis & treatment market is expected to grow at a CAGR (Compound Annual Growth Rate) of about 7.84% in the coming years.

Bacteria, viruses, fungi, and parasites are all responsible for infectious disorders. These illnesses can be spread by insects, animals, contaminated food or drink, or exposure to an infected environment. The market is predicted to escalate due to the rising incidence of infectious illnesses and increased awareness of these diseases. According to a World Health Organization (WHO) report, almost 50,000 people die every day due to infectious diseases.

In February 2024, at MWC Barcelona Huawei officially unveiled its Medical Technology Digitalization Solution as part of spearheading the healthcare industry’s digital and intelligent Upgrade. This focuses on pathology and medical imaging. These include SmartCache intelligent pre-reading, improving image reading efficiency and achieving zero latency during data retrieval; Huawei-developed compression algorithm saving up to %30 storage and %70 cabinet space; and video-network synergy offering consistent remote diagnosis for promoting hierarchical diagnosis and treatment.

SymphonyAI, a leading provider of predictive and generative enterprise AI SaaS solutions, announced SensaAI for sanctions, which is available now as a “platform agnostic AI upgrade” for any sanction’s solution in APAC at Money20/20 Asia held in April this year. It dramatically impacts sanctions evasion efforts via optimizers' match accuracy using deep context-aware AI-based matching algorithms. Delivered through an API (application programming interface), SensaAI for sanctions is pre-trained, so ready to go out of the box.

Leveraging the organization’s current data, SensaAI for sanctions functions in tandem with AI-powered rules-based systems that drive the match process from rationalizing unstructured data containing SWIFT transaction data.

In April 2023, EliTech plans to introduce EliVerse-an automated high throughput molecular diagnostics instrument into European market by 2024.

In April 2023, Cepheid announced its plan to develop new tests for various infectious diseases such as tuberculosis and respiratory diseases among others in year 2023; this company is one of Danaher’s subsidiaries.

For instance, ELITechGroup outlined their forthcoming high throughput sample-to-result molecular diagnostics instrument in April 2023.

In February 2023,Thermo Fisher Scientific Inc joined forces with MyLab in purchasing RT-PCR kits used for diagnosing various infectious diseases like tuberculosis & HIV. Attraction for more consumers has been made by self-testing kits for HIV infections.

Thermo Fisher Scientific Inc. launched its CE – IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit in January 2023. This move strengthens therapeutic efficacy, encourages viral resistance monitoring, and advances infectious disease market innovation

In July 2022, Roche launched Elecsys HCV Duo, an immunoassay that enables independent and simultaneous determination of hepatitis C virus (HCBv) antigen and antibody status from a single human plasma or serum sample. This discovery improves diagnostic efficiency, streamlines patient management and further enhances the handling of infections diseases that would ultimately push the growth of the market.

In May 2022 The U.S. Food and Drug Administration (FDA) has granted Abbott emergency use authorisation (EUA) for its fastest available molecular point-of-care test which detects new corona virus(COVID-19) results in positive within five minutes and negatives in thirteen minutes.

In May 2022 Quidel Corporation has announced its acquisition of Ortho Clinical Diagnostics as well as other affiliated business groups being a US-based company offering rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems.

Torus Biosystems disclosed series A financing of USD 25 million to propel improved healthcare settings infectious disease diagnostics during May 2022.

**Covid-19 Analysis**

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The infectious illnesses diagnosis & treatment market saw a slight downfall due to the lockdown and physical distancing.

However, the key companies have adopted measures to expand the distribution of infectious illnesses treatment and diagnosis equipment across the globe. Moreover, people are growing aware of infectious diseases, and the price of pharmaceutical products is increasing. Hence, these factors are expected to boost the APAC infectious disease diagnosis & treatment market value in the years to come.

## **Asia Pacific Infectious Disease Diagnosis & Treatment Market Trends**

**Drivers**

Infectious illness prevalence in both established and emerging nations would boost the APAC infectious disease diagnosis & treatment market growth. The rising number of prescriptions for infectious illness diagnostic tests is due to diagnosing and managing such disorders. Over the forecast period, these factors, together with the increasing tendency toward preventative care, are projected to increase demand for APAC infectious disease diagnosis & treatment market.

**Opportunities **

Due to multiple major and minor significant players, the infectious illnesses treatment & diagnosis market seems fragmented. These market participants attempt to acquire a competitive edge through strategic initiatives such as partnership, acquisition, expansion, cooperation, and product and technology launches. Significant efforts are being made in R&D to produce unique diagnoses & treatment options.

**Restraints **

A few factors may inhibit the growth of the APAC infectious disease diagnosis & treatment market share.** **The development of the infectious illness treatment market is likely to be hampered by stringent government restrictions and a lack of information about treatment choices in developing nations. Inadequate reimbursement is a key stumbling block to the infectious disease diagnostics market's development.

**Challenges **

There are various concerns with the market that may challenge the key players of the APAC infectious disease diagnosis & treatment market. This includes the cost of the diagnosis and treatment solutions. High treatment and maintenance costs for infectious diseases and a lack of infrastructure in medium and low-income nations may limit the expansion of the market. Most diagnostic companies have a significant challenge in commercializing their tests, convincing their health insurance to pay for them.

**Cumulative Growth Analysis**

The APAC infectious disease diagnosis & treatment market is anticipated to grow substantially in the years to come. The infectious illness market value was estimated at around USD 179.58 Billion in 2018 and is expected to grow at a CAGR of about 7.84% in the coming years.

**Value Chain Analysis**

During the APAC infectious disease diagnosis & treatment market forecast, demand for diagnostics is likely to be driven by the expanding trend of preventive medicine. To strengthen Covid-19 preventive and control efforts, large-scale population-based testing is necessary. Infectious illness diagnostics performs these tests. Hence, it is likely to have a favorable influence on APAC infectious disease diagnosis & treatment market.

Developing economies such as India, South Korea, Brazil, and Mexico will likely provide significant infectious illness diagnostics market participants with new growth prospects. The high illness incidence, big patient population, better healthcare infrastructure, increasing disposable money, and growing medical tourism in these nations contribute to this. Aside from the aforementioned characteristics, the Asia Pacific region has grown as a flexible and business-friendly center due to less strict rules and data requirements.

## **Asia Pacific Infectious Disease Diagnosis & Treatment Market Segmentation**

The global APAC infectious disease diagnosis & treatment market is classified into many segments such as disease types, treatment, and end-user. Listed below are the infectious illness treatment & diagnosis market segments:

### **Disease Type Outlook**

### **Treatment Outlook**

### **End-user Outlook**

**Regional Analysis**

The regional division of the APAC infectious disease diagnosis & treatment market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. The Americas are expected to dominate the infectious disease treatment market due to a rising patient population suffering from different kinds of infectious illnesses and a growing number of government efforts to prevent contagious diseases in the area.

Due to rising awareness and an increasing patient population suffering from severe infectious diseases, Europe is expected to hold the second-largest position in the APAC  infectious disease diagnosis & treatment market. According to the WHO, 14 million people in Europe are infected with hepatitis C as of 2018. Due to the huge patient population suffering from [bacterial](../../../reports/bacterial-cell-culture-market-696) infectious illnesses and the increasing number of activities conducted by governments and private organizations to raise awareness about infectious diseases, Asia-Pacific is predicted to be the fastest-growing regional market.

According to a May 2018 study released by the National Center for Biotechnology Information (NCBI), meningitis and pneumonia account for roughly 22% of mortality among children under five in India. Because of the expanding patient population suffering from various infectious illnesses, the APAC infectious disease diagnosis & treatment market in the Middle East and Africa is predicted to rise slowly.

**Competitive Landscape **

The infectious disease diagnosis & treatment industry is dominated by a few companies that play a vital role in the market growth. These infectious illnesses diagnosis and treatment provider companies are called key companies of the market. They contribute to the largest share of the APAC infectious disease diagnosis & treatment market profit.

The companies account for the market profits by adopting various APAC infectious disease diagnosis & treatment market trends such as joint ventures, product launches, company expansions, and procurements. They provide innovative solutions for patients suffering from infectious illnesses.

**Key Players**

Below are the key companies that offer infectious illness diagnosis and treatment solutions in the global APAC infectious disease diagnosis & treatment market, along with the location of their headquarters:

Recent Development November 2023: Abbott Laboratories announces the launch of its new Panbio™ COVID-19 Ag Rapid Test Nasal, a rapid antigen test for COVID-19 that can be performed in just 15 minutes using a nasal swab. The test is designed for professional use and is intended to be used as an aid in the diagnosis of COVID-19 infection.Becton, Dickinson and Company (BD) announces the launch of its new BD MAX™ System for the detection of Omicron subvariants.

The BD MAX™ System is a molecular diagnostic platform that can be used to detect a wide range of infectious pathogens, including viruses, bacteria, and fungi.Roche Diagnostics announces the launch of its new cobas® Liat® System MRSA Test, a rapid molecular diagnostic test for the detection of methicillin-resistant Staphylococcus aureus (MRSA). The cobas® Liat® System MRSA Test is designed to be used in point-of-care settings and can provide results in less than 60 minutes.

October 2023: Thermo Fisher Scientific announces the launch of its new Applied Biosystems™ TaqMan™ SARS-CoV-2 Mutation Assays, which are designed to detect and differentiate between the most common SARS-CoV-2 variants of concern. The Applied Biosystems™ TaqMan™ SARS-CoV-2 Mutation Assays can be used on a variety of Thermo Fisher Scientific real-time PCR instruments.Qiagen announces the launch of its new QIAprep® Viral RNA Mini Kit Plus, a high-performance kit for the extraction of viral RNA from a variety of sample types, including nasopharyngeal swabs, saliva, and wastewater.

The QIAprep® Viral RNA Mini Kit Plus is designed to be used with a variety of molecular diagnostic platforms, including the Qiagen QIAcuity™ and QIAcube™ instruments.

## Market Drivers

### Rising Healthcare Expenditure

The increase in healthcare expenditure across APAC countries is a significant driver for the infectious disease-diagnosis-treatment market. Governments and private sectors are allocating more funds towards healthcare infrastructure, which includes the procurement of diagnostic tools and treatment options for infectious diseases. For instance, healthcare spending in countries like India and China has been rising steadily, with projections indicating a growth rate of around 7% annually. This increased investment is likely to enhance the availability and accessibility of diagnostic services, thereby fostering market growth in the region. As healthcare budgets expand, the infectious disease-diagnosis-treatment market is poised to benefit from improved resources and capabilities.

### Growing Burden of Infectious Diseases

The rising incidence of infectious diseases in APAC is a critical driver for the infectious disease-diagnosis-treatment market. Countries in this region are experiencing an increase in diseases such as tuberculosis, malaria, and dengue fever. For instance, the World Health Organization reported that tuberculosis cases in APAC accounted for approximately 60% of the global total in recent years. This growing burden necessitates enhanced diagnostic and treatment solutions, prompting healthcare providers to invest in advanced technologies. The increasing prevalence of these diseases is likely to drive demand for innovative diagnostic tools and effective treatment options, thereby expanding the market significantly.

### Technological Innovations in Diagnostics

Technological advancements in diagnostic tools are transforming the infectious disease-diagnosis-treatment market in APAC. Innovations such as rapid diagnostic tests, molecular diagnostics, and point-of-care testing are becoming increasingly prevalent. For example, the market for molecular diagnostics in APAC is projected to grow at a CAGR of around 10% over the next few years. These technologies enable quicker and more accurate detection of infectious diseases, which is crucial for timely treatment. As healthcare systems in APAC adopt these innovations, the market is expected to witness substantial growth, driven by the demand for efficient and reliable diagnostic solutions.

### Public Awareness and Education Initiatives

Public awareness campaigns and education initiatives regarding infectious diseases are playing a pivotal role in driving the infectious disease-diagnosis-treatment market in APAC. Governments and non-governmental organizations are increasingly focusing on educating the population about prevention, early detection, and treatment options. This heightened awareness is likely to lead to increased testing and treatment-seeking behavior among the public. As individuals become more informed about the risks associated with infectious diseases, the demand for diagnostic services is expected to rise. Consequently, this trend may contribute to the overall growth of the infectious disease-diagnosis-treatment market in the region.

### Collaboration Between Public and Private Sectors

The collaboration between public and private sectors is emerging as a vital driver for the infectious disease-diagnosis-treatment market in APAC. Partnerships between governments, healthcare providers, and private companies are fostering innovation and improving access to diagnostic and treatment solutions. These collaborations often lead to the development of new technologies and the sharing of resources, which can enhance the efficiency of healthcare delivery. For instance, joint initiatives aimed at combating infectious diseases have been established in several APAC countries, resulting in improved diagnostic capabilities. This synergy is likely to propel the market forward, as it encourages the adoption of advanced solutions and expands the reach of healthcare services.

## Future Outlook

The infectious disease-diagnosis-treatment market is projected to grow at 2.27% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare investments.

**New opportunities:**

- Development of AI-driven diagnostic tools for rapid disease identification.
- Expansion of telemedicine platforms for remote patient monitoring.
- Investment in point-of-care testing devices for enhanced accessibility.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Diagnosis Method: Molecular Diagnostics (Largest) vs. Rapid Diagnostic Tests (Fastest-Growing)

In the diagnosis method segment, [Molecular Diagnostics](https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171) holds the largest market share due to its advanced accuracy and capability to detect pathogens at a molecular level. This segment has been widely adopted for its precision in diagnosing infectious diseases, significantly outpacing other methods such as Serological Tests and Culture Methods. Rapid Diagnostic Tests are emerging with a growing market share, offering quick results and enhancing point-of-care testing, although they are currently not as widely utilized as Molecular Diagnostics. The growth trends in this segment are driven by technological advancements and an increasing demand for early diagnosis of infectious diseases. The COVID-19 pandemic accelerated the adoption of Molecular Diagnostics and Rapid Diagnostic Tests, highlighting the need for rapid and accurate testing protocols. Additionally, government initiatives and funding for improved diagnostic technologies are contributing to the rapid expansion and innovation within this market segment, especially for Rapid Diagnostic Tests, which are expected to gain significant traction in the coming years.

Molecular Diagnostics (Dominant) vs. Rapid Diagnostic Tests (Emerging)

Molecular Diagnostics stands out in the diagnosis method segment as the dominant force, providing unparalleled accuracy and specificity in identifying infectious diseases at a genetic level. This method includes techniques such as PCR and sequencing, which allow for rapid and reliable detection of pathogens. The widespread adoption of Molecular Diagnostics is fueled by an increased focus on precision medicine and the need for swift diagnostic solutions. Conversely, Rapid Diagnostic Tests are emerging as a vital component in disease management, particularly in settings where time is of the essence. These tests offer quick and convenient results, enabling healthcare providers to make timely decisions. Although they currently represent a smaller share of the market, their growth potential is significant, driven by their ability to facilitate rapid diagnosis and improve access to testing.

### By Treatment Type: Antibiotics (Largest) vs. Vaccines (Fastest-Growing)

The Treatment Type segment of the infectious disease diagnosis and treatment market reveals a diverse distribution among its values. Antibiotics hold the largest share, significantly leading in market presence due to the longstanding reliance on these medications in managing bacterial infections. Following antibiotics, antivirals and antifungals contribute notably, while vaccines are emerging as a critical component amid global vaccination drives, aiming to combat infectious diseases more effectively. In terms of growth trends, the demand for antivirals and especially vaccines is seeing a rapid increase, driven by heightened awareness surrounding infectious diseases and the urgent need for preventive measures. With advancements in vaccine technology and increased governmental support for immunization programs, vaccines are poised for substantial growth in the coming years. Meanwhile, antibiotic resistance poses challenges that will demand innovative treatments, ensuring that this segment remains dynamic and adaptable.

Antibiotics: Dominant vs. Vaccines: Emerging

Antibiotics are currently the dominant force in the Treatment Type segment, accounting for a significant portion of the market due to their established efficacy in treating bacterial infections. These medications are widely prescribed, contributing to their strong market position. On the other hand, vaccines represent an emerging area with immense potential, especially as public health initiatives push for increased immunization. With innovative developments and a growing recognition of their role in preventing infectious diseases, vaccines are gaining momentum. This duality highlights the ongoing need for antibiotics while indicating a shift towards preventive healthcare through vaccination, marking a transformative phase in infectious disease management.

### By Infectious Disease Type: Bacterial Infections (Largest) vs. Viral Infections (Fastest-Growing)

In the infectious disease diagnosis and treatment market, bacterial infections hold the largest share, significantly dominating the segment composition. Following closely are viral infections, which are rapidly gaining traction and account for a notable portion of the market. Fungal and parasitic infections, while essential to address, have smaller shares comparatively but still contribute to the diverse infectious disease landscape. Growth trends indicate that the market is witnessing a surge in viral infections, attributed to factors like increased travel, urbanization, and a rise in immunocompromised populations. Meanwhile, bacterial infections remain prevalent due to antibiotic resistance, prompting innovations in diagnostic and treatment technologies. As a consequence, investment in both segments is expected to escalate, aligning with the evolving public health demands.

Bacterial Infections (Dominant) vs. Fungal Infections (Emerging)

Bacterial infections represent the dominant force in the infectious disease diagnosis and treatment landscape, characterized by persistent prevalence and critical need for effective diagnostics and treatments. Innovations in antibiotic therapies and robust diagnostic tools are driven by rising bacterial resistance. In contrast, fungal infections are emerging, recognized as a growing concern with increasing incidence rates. They often affect immunocompromised patients more severely. The market for fungal infections is evolving, with significant investments channeled towards developing novel antifungal agents and rapid diagnostic tests. This shift is reflective of an increasing awareness of fungal diseases and their impact on health, particularly in hospital settings.

### By End User: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

In the APAC infectious disease-diagnosis-treatment market, Hospitals hold the largest market share due to their extensive facilities and resources to conduct complex diagnostic procedures. They serve as primary centers for the diagnosis and treatment of infectious diseases, leading to a higher patient inflow and consequently a larger share within the segment. Clinical Laboratories and Research Institutes follow, contributing significantly but not at the scale of Hospitals, while Home Care Settings are gaining traction with the rise of at-home healthcare services. Growth trends indicate a significant shift towards Home Care Settings as patients increasingly prefer treatment in the comfort of their homes. This change is driven by advancements in telemedicine and diagnostic technologies, which facilitate remote monitoring and treatment. Furthermore, the COVID-19 pandemic has accelerated the adoption of these settings, making them a vital part of the healthcare landscape in the region.

Hospitals (Dominant) vs. Home Care Settings (Emerging)

Hospitals are the cornerstone of the infectious disease-diagnosis-treatment market in the APAC region, dominating due to their ability to provide comprehensive care and advanced diagnostic capabilities. They are equipped with state-of-the-art technologies and staffed by skilled professionals, allowing for rapid diagnosis and effective treatment. In contrast, Home Care Settings are emerging as a viable alternative, especially for mild to moderate cases. With growing patient acceptance, advancements in home diagnostics, and increasing support from healthcare policies, these settings are catering to the evolving preferences of patients, reflecting a paradigm shift towards more personalized and accessible healthcare solutions.

## Regional Market Share Analysis

### China : Robust Growth Driven by Innovation

China holds a commanding 10.5% market share in the infectious disease diagnosis and treatment sector, valued at approximately $XX billion. Key growth drivers include increasing healthcare expenditure, rapid urbanization, and a rising prevalence of infectious diseases. Government initiatives, such as the Healthy China 2030 plan, aim to enhance healthcare infrastructure and accessibility. The regulatory environment is becoming more favorable, with streamlined approval processes for diagnostic products.

### India : Rapid Growth in Healthcare Investments

India's market share stands at 6.8%, reflecting a burgeoning demand for infectious disease diagnostics. The growth is fueled by increasing awareness of healthcare, government initiatives like Ayushman Bharat, and a growing middle class. The demand for rapid testing and point-of-care diagnostics is on the rise, supported by advancements in technology and infrastructure improvements in urban areas.

### Japan : Innovation and Quality Drive Market

Japan accounts for 4.5% of the APAC market, characterized by high-quality standards and advanced technology in diagnostics. The aging population and increasing healthcare needs are significant growth drivers. Regulatory frameworks are stringent, ensuring high safety and efficacy standards. The government supports research and development, fostering innovation in diagnostic technologies.

### South Korea : Healthcare Innovation and Accessibility

South Korea holds a 3.2% market share, driven by a robust healthcare system and technological advancements. The government promotes health initiatives and invests in healthcare infrastructure, enhancing access to diagnostic services. The demand for rapid and accurate testing is growing, particularly in urban centers like Seoul and Busan, where healthcare facilities are concentrated.

### Malaysia : Investment in Healthcare Infrastructure

Malaysia's market share is 1.8%, with significant growth potential driven by government initiatives like the National Health Policy. The increasing prevalence of infectious diseases and a focus on improving healthcare access are key growth factors. The regulatory environment is evolving, supporting the introduction of innovative diagnostic solutions in the market.

### Thailand : Healthcare Reforms and Investments

Thailand's market share is 1.5%, supported by ongoing healthcare reforms and investments in public health. The demand for infectious disease diagnostics is rising, driven by increased awareness and government initiatives. Key cities like Bangkok and Chiang Mai are central to market activities, with a competitive landscape featuring both local and international players.

### Indonesia : Focus on Healthcare Accessibility

Indonesia's market share is 0.8%, with significant opportunities for growth in infectious disease diagnostics. The government is focusing on improving healthcare access through initiatives like the National Health Insurance program. Urban areas such as Jakarta are seeing increased demand for diagnostic services, although challenges remain in rural healthcare delivery.

### Rest of APAC : Varied Growth Across Sub-regions

The Rest of APAC holds a 0.5% market share, characterized by diverse healthcare landscapes and varying levels of infrastructure development. Growth is driven by localized healthcare needs and government initiatives aimed at improving public health. Each country presents unique challenges and opportunities, influenced by economic conditions and regulatory environments.

## Competitive Benchmarking

The infectious disease-diagnosis-treatment market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of infectious diseases, and a growing emphasis on rapid diagnostics. Major players such as Abbott Laboratories (US), Roche Holding AG (CH), and Thermo Fisher Scientific Inc. (US) are strategically positioned to leverage innovation and regional expansion to enhance their market presence. Abbott Laboratories (US) focuses on developing cutting-edge diagnostic solutions, while Roche Holding AG (CH) emphasizes partnerships to bolster its product offerings. Thermo Fisher Scientific Inc. (US) is actively pursuing mergers and acquisitions to diversify its portfolio, collectively shaping a competitive environment that prioritizes innovation and responsiveness to market needs.
Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a variety of approaches to emerge, as companies seek to differentiate themselves through unique product offerings and strategic collaborations.
In October 2025, Abbott Laboratories (US) announced the launch of a new rapid diagnostic test for infectious diseases, which is expected to significantly reduce time-to-results. This strategic move not only enhances Abbott's product portfolio but also positions the company to meet the increasing demand for rapid testing solutions in the APAC region. The introduction of this test may potentially strengthen Abbott's competitive edge by addressing urgent healthcare needs.
In September 2025, Roche Holding AG (CH) expanded its partnership with a leading biotechnology firm to co-develop next-generation diagnostic tools. This collaboration is indicative of Roche's commitment to innovation and reflects a broader trend of strategic alliances aimed at enhancing technological capabilities. Such partnerships may enable Roche to accelerate the development of advanced diagnostics, thereby reinforcing its market position.
In August 2025, Thermo Fisher Scientific Inc. (US) completed the acquisition of a prominent diagnostics company, enhancing its capabilities in infectious disease testing. This acquisition is likely to provide Thermo Fisher with access to new technologies and markets, further solidifying its role as a leader in the diagnostics space. The integration of these new assets may facilitate the development of comprehensive solutions that cater to diverse customer needs.
As of November 2025, current competitive trends in the infectious disease-diagnosis-treatment market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a greater emphasis on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, ultimately enhancing their ability to respond to emerging challenges.

## Report Scope

| MARKET SIZE 2024 | 28.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 29.15(USD Billion) |
| MARKET SIZE 2035 | 36.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.27% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Holding AG (CH), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (DE), Becton Dickinson and Company (US), bioMérieux SA (FR), Cepheid (US), Hologic Inc. (US), QuidelOrtho Corporation (US) |
| Segments Covered | Diagnosis Method, Treatment Type, Infectious Disease Type, End User |
| Key Market Opportunities | Integration of advanced diagnostics and telemedicine enhances access to infectious disease-diagnosis-treatment solutions. |
| Key Market Dynamics | Rising demand for rapid diagnostic tests drives innovation in the infectious disease-diagnosis-treatment market. |
| Countries Covered | China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC |

## Frequently Asked Questions

**Q: What is the projected market valuation for the APAC infectious disease-diagnosis-treatment market in 2035?**
A: The projected market valuation for 2035 is $36.5 Billion.

**Q: What was the overall market valuation in 2024?**
A: The overall market valuation was $28.5 Billion in 2024.

**Q: What is the expected CAGR for the APAC infectious disease-diagnosis-treatment market from 2025 to 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 2.27%.

**Q: Which diagnostic method segment is projected to grow the most by 2035?**
A: Molecular Diagnostics is projected to grow from $8.55 Billion in 2024 to $10.25 Billion by 2035.

**Q: What are the projected values for the treatment type segment of antibiotics by 2035?**
A: The projected value for antibiotics is expected to rise from $8.5 Billion in 2024 to $10.5 Billion by 2035.

**Q: How much is the viral infections segment expected to be valued at by 2035?**
A: The viral infections segment is expected to be valued at $12.5 Billion by 2035, up from $10.2 Billion in 2024.

**Q: What is the anticipated growth for the home care settings end user segment by 2035?**
A: The home care settings segment is anticipated to grow from $5.0 Billion in 2024 to $6.0 Billion by 2035.

**Q: Which key players are leading the APAC infectious disease-diagnosis-treatment market?**
A: Key players include Abbott Laboratories, Roche Holding AG, and Thermo Fisher Scientific Inc.

**Q: What is the projected value for the serological tests segment by 2035?**
A: The serological tests segment is projected to reach $8.0 Billion by 2035, increasing from $6.5 Billion in 2024.

**Q: What is the expected growth for antifungals in the treatment type segment by 2035?**
A: Antifungals are expected to grow from $5.0 Billion in 2024 to $7.5 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/apac-infectious-disease-diagnosis-treatment-market-1322*